BSX

Boston Scientific Corporation Common Stock (BSX)

Stock · NYSE · Health Care

$46.84as of 8/28/2026

AI Market Commentary

AI-generated

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

August 29, 2026

BSX Faces Cybersecurity Disruption as Broader Market Pressure Builds. Boston Scientific disclosed a global disruption tied to a cybersecurity incident, drawing market attention to the medical device maker on an otherwise difficult day for equities. Broader market jitters, including renewed rate-hike concerns following a hot PCE inflation reading, weighed on sentiment, yet BSX was also flagged among notable S&P 500 movers and gapping stocks. Separately, an independent screen highlighted BSX as a quality name, though the company was navigating operational headwinds from the cyber event at the time. The combination of company-specific news and macro pressure made the stock one of the more actively discussed names in recent sessions.

Active signals

Support level
$44.28
Industry
Medical/Dental Instruments

About BSX

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scop…

Sector
Health Care
Industry
Medical/Dental Instruments
Employees
59,000

Fundamentals

1-day range
$46.51$47.22
Market cap
$71.98B
P/E (trailing)
20.40
P/E (forward)
13.64
EPS (trailing)
$2.47
Dividend yield
Beta
0.57
Avg. volume
20.39M
52-week range
$42.2$109.5
Next earnings: October 28, 2026 · EPS estimate $0.81Before Openconfirmed

How Boston Scientific Corporation Common Stock Makes Money

Where the revenue actually goes — FY2025 annual results

market-wall.comTotalRevenue$20.07BNet Income$2.89B (14%)SG&A$6.89B (34%)Cost of Revenue$6.22B (31%)Other$3.58B (18%)Tax$493.00M (2%)BSX

Source: 10-K filed Feb 17, 2026 · via SEC EDGAR / Finnhub

Forecasts

29 analyst ratings

Buy 79%
Hold 21%
Sell 0%
1-year price forecast
High
$94
+100.7%
Median
$60
+28.1%
Low
$44
-6.1%

Boston Scientific Corporation Common Stock Competitors

Chosen by industry and closest market cap.

  • BSX
    Boston Scientific Corporation Common Stock
    $46.83
    ▲ 0.34%
    Market cap $71.98BP/E 20.40
    $42.2$109.5
  • MDLN
    Medline Inc. Class A Common Stock
    $35.29
    ▲ 1.85%
    Market cap $53.16BP/E 67.50
    $32.49$50.88
  • BDX
    Becton Dickinson and Company Common Stock
    $189.6
    ▲ 0.78%
    Market cap $46.90BP/E 53.21
    $127.59$193.07
  • DXCM
    DexCom Inc. Common Stock
    $90.8
    ▲ 1.69%
    Market cap $32.95BP/E 34.53
    $54.11$92.59
  • RMD
    ResMed Inc. Common Stock
    $240.24
    ▲ 1.90%
    Market cap $31.21BP/E 21.47
    $180.27$285.08
  • BAX
    Baxter International Inc. Common Stock
    $26.12
    ▲ 0.77%
    Market cap $14.53BP/E
    $15.73$30
  • SYK
    Stryker Corporation Common Stock
    $330.67
    ▲ 2.65%
    Market cap $130.80BP/E 35.17
    $281$396.86

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

Insider Activity

Insider Actions
Acquired
301.8K
Disposed
387.8K

Institutional Ownership

March 31, 2026

Total shares held
1.29B
Total value held
$78.05B
Institutional holders
1650
Top holders this quarter
  • Unknown131.82M
  • Unknown96.41M
  • Unknown74.23M
  • Unknown67.99M
  • Unknown33.29M
  • Unknown32.53M
  • Unknown24.43M
  • Unknown22.76M
  • Unknown22.27M
  • Unknown19.37M

See the full, filterable feed with live charts on the MarketWall dashboard.

We use analytics to understand how market-wall is used. No personal data is sold.